Estrogen Down-regulator Fulvestrant Potentiates Antitumor Activity of Fluoropyrimidin in Estrogen-responsive MCF-7 Human Breast Cancer Cells

MAMORU NUKATSUKA1, HITOSHI SAITO2, SHINZABURO NOGUCHI3 and TEIJI TAKECHI1

1Translational Research Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan;
2Pharmacology Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan;
3Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

Abstract. Background: Endocrine therapy is clinically administered in hormone-responsive breast cancer. Combinations of fluoropyrimidine S-1 and an aromatase inhibitor or anti-estrogen are considered beneficial in Japan. Herein we assessed new combinations of S-1 and fulvestrant.

Patients and Methods: Cytotoxicity of fulvestrant and 5-fluorouracil (5-FU) was assessed in hormone-responsive (MCF-7) and non-responsive (MDA-MB-231) breast cancer cell cultures. Fulvestrant and S-1 were evaluated for antitumor activity in mice and their effects on estrogen receptor (ER)-α and progesterone receptor (PgR) levels in MCF-7 xenografts using immunohistochemical methods.

Results: Fulvestrant inhibited growth of MCF-7, but not of MDA-MB-231 xenografts. Combinations of 5-FU and fulvestrant were superior to monotherapy in vitro. In vivo antitumor activity of S-1/fulvestrant combination therapy was significantly (p<0.05) enhanced compared to that of both monotherapies. Fulvestrant partially down-regulated expression of ERα and PgR, but in combination with S-1, it almost completely blocked their expression. Conclusion: Chemo-endocrine combination therapy using S-1 and fulvestrant is beneficial in estrogen-responsive breast cancer.

Breast cancer is the most common cancer in women around the world, including in the United States (1, 2) and Japan, where it remains the fifth-leading cause of cancer-related death (3). Endocrine therapy is a well-established first-line treatment for estrogen receptor (ER)-α-positive, metastatic breast cancer (4). Current endocrine therapy treatment options for menopausal patients with hormone-responsive breast cancer include selective ERα modulators (e.g. tamoxifen), aromatase inhibitors (e.g. anastrozole, letrozole, and exemestane), and, in addition, selective ERα down-regulators (e.g. fulvestrant). An evaluation of several clinical trials of combination therapies testing fulvestrant with cyclin-dependent kinase 4 and 6 inhibitors [PALOMA-3 (5), MONALEESA-3 (6), and MONARCH2 (7)] or phosphoinositide 3-kinase inhibitors [FERG1 (8), BELLE-2 (9), BELLE-3 (10)] indicated that combination with the cyclin-dependent kinase 4 and 6 inhibitor palbociclib was associated with a significantly extended progression-free survival as compared with that of fulvestrant monotherapy. According to the guideline from the European Society for Medical Oncology, antagonistic interactions are predicted to occur using combination therapy of endocrine therapy and chemotherapy, and, therefore, simultaneous chemo-endocrine therapy is not recommended (11).

However, in contrast to other chemotherapeutic agents, clinical trials in Japan showed that only tegafur (a masked 5-FU derivative)/uracil (UFT), an oral fluoropyrimidine, used in combination with tamoxifen, improved overall survival, compared to surgery alone (12, 13). Furthermore, there was no significant difference in relapse-free survival between those treated with UFT therapy and cyclophosphamide/methotrexate/5-fluorouracil (5-FU) therapy (14, 15). We attempted to confirm the conclusions of this clinical trial. In vitro studies on ER-positive human breast cancer cell lines KPL-1 and ML-20 showed that 4-OH-tamoxifen exerted synergistic inhibitory effects with 5-FU but not with doxorubicin or paclitaxel (16). Furthermore, in vitro growth inhibition by 5-FU was assessed in the presence and absence of 17β-estradiol (E2). Growth of KPL-1 and ML-20 cells was inhibited in E2-depleted fetal
bovine serum (FBS), which mimics the status after treatment with an aromatase inhibitor (17).

Oral fluoropyrimidine S-1 contains tegafur in combination with gimeracil (a potent inhibitor of 5-FU degradation) and potassium oxonate at a molar ratio of 1: 0.4: 1; the combination has lower gastrointestinal toxicity by blocking 5-FU activation in the gastrointestinal tract (18, 19). S-1 is considered beneficial and is approved as a clinical therapy for gastric (20), breast (21) and other solid tumor types in over 40 countries. S-1 potentiates the antitumor activity of anastrozole in vitro as observed using an aromatase-transfected, ER-positive human breast cancer cell line, and in vivo (22). In addition to aromatase inhibitors, the specific ER down-regulator fulvestrant (23) is approved for menopausal patients with hormone-responsive breast cancer (24-26). However, studies on combination therapies consisting of fulvestrant and other chemotherapeutics are limited. In this study, we aimed to evaluate a new chemoendocrine therapy using S-1 in combination with fulvestrant.

Patients and Methods

Chemicals. Tegafur, gimeracil, and potassium oxonate were obtained from Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan). Fulvestrant was purchased from Funakoshi Co., Ltd. (Tokyo, Japan). E2, Dulbecco’s modified Eagle’s medium/Ham’s F-12 (1:1) and FBS were purchased from Sigma–Aldrich Japan (Tokyo, Japan). SE-121 pellet, which contained 0.025 mg E2/pellet for a 60-day release period, was obtained from Innovative Research of America (Sarasota, FL, USA). Hydroxypropyl methylcellulose was purchased from Shin-Etsu Chemical Co., Ltd. (Tokyo, Japan), 5-FU, peanut oil, dimethyl sulfoxide (DMSO), and crystal violet were purchased from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan). All other reagents were commercially available products of the highest grade.

Antibodies. Rabbit monoclonal antibodies to human ERα (ab16660, Clone SP1) and human progesterone receptor (PgR) (ab16661, Clone SP2) were purchased from Abnova Japan KK (Tokyo, Japan). Horseradish peroxidase-conjugated goat anti-rabbit IgG Fab fragment HistostarTM (Rb) for mouse tissue analysis was purchased from Medical & Biological Laboratories Co., Ltd. (Nagoya, Japan) and used for immunohistochemical (IHC) staining.

In vitro cell culture and growth inhibition testing. ER-positive human breast cancer cell line MCF-7, originally obtained from the American Tissue Culture Collection (ATCC, Rockville, MD, USA), was kindly provided by the Osaka University Graduate School of Medicine (Osaka, Japan) and ER-negative human breast cancer cell line MDA-MB-231 was purchased from the ATCC. MCF-7 was cultured using DMEM/Ham’s F-12 (1:1) supplemented with 0.1 nM E2, 10% FBS and Glutamax™ (Life Technologies Japan Ltd, Tokyo, Japan). MDA-MB-231 was cultured using RPMI-1640 supplemented with 10% FBS at 37°C with 5% CO2. Cells were collected using TrypLESTM Express (Life Technologies Japan Ltd, Tokyo, Japan) and seeded into 96-well plates at a density of 3,000 cells/well on day 0. The in vitro E2 concentration was equivalent to the serum level in mice achieved by administering the E2 pellet based on our previous experiment (data not shown). Fulvestrant and 5-FU were dissolved in DMSO and diluted with culture medium on day 1. The final DMSO concentration was less than 0.5%. Cell growth rates were determined colorimetrically on day 6 by crystal violet staining according to the method reported by Saotome et al. (27). The concentration inhibiting cell growth by 50% (IC50) was calculated by regression analysis.

Interactions between 5-FU and fulvestrant against MCF-7 cells were analyzed using the isobologram method (28). The dose–response curves for treatment with 5-FU and fulvestrant alone were used to derive three isoeffect curves (Mode I, IIA, and IIB), which were analyzed in relation to the IC50 values. The areas enclosed by the three isoeffect curves shown in Figure 2 indicate the envelope. The data points located within the envelope represent additive effects, and data points below the envelope represent supra-additive effects.

In vivo antitumor activity. Five-week-old female BALB/cAcl nulado mice were purchased from CLEA Japan Inc. (Tokyo, Japan) and housed under specific pathogen-free conditions; food and water were provided ad libitum. After the animals had been in quarantine for 5 days, SE-121 pellet (0.025 mg E2/pellet) was implanted into the left flank subcutaneously. Because high E2 doses were found to be associated with high mortality in mice due to renal toxicity in a preliminary experiment, one pellet containing 0.025 mg E2 per animal was identified as the optimal amount (data not shown).

One week after the procedure, MCF-7 cells suspended in saline were injected in the right axillary subcutaneously at a dose of 4×10⁶ cells per mouse. To evaluate the antitumor activity, the mice were randomized according to tumor volume once the mean tumor volume reached approximately 38-46 mm³ (day 0). Each group consisted of seven mice. One group of mice with no tumor- and SE-121-pellet-free was used as negative control (n=7).

S-1 was prepared by mixing tegafur, gimeracil, and potassium oxonate at a molar ratio of 1:0.4:1 in 0.5% hydroxypropyl methylcellulose. S-1 was administered orally at the reported effective dose (10 mg/kg, at 10 ml/kg) (18) once daily for 18 consecutive days. Fulvestrant was dissolved in peanut oil and administered into the left femor subcutaneously on day 1 at a dose of 5 mg in 50 μl per animal.

The tumor diameters were measured twice a week until day 18, the last day of administration, and the tumor volume was estimated using the formula 0.5×length × width².

All the animal studies were performed according to the guidelines of and approved by the Institutional Animal Care and Use Committee at Taiho Pharmaceutical Co., Ltd. (Approval Number: 17PB06).

HIC staining of ERα and PgR. To perform the IHC staining on mouse tissue, tumors were excised on day 19, the day after the last S-1 administration, fixed in 10% phosphate-buffered formaldehyde (pH 7.4) for 1 day followed by the preparation of paraffin-embedded tissue sections according to the conventional method. Heat-induced antigen retrieval was applied using a pressure cooker at 121°C for 5 min in Tris-Borate-EDTA buffer (Takara Bio Inc., Kusatsu, Japan) at pH 8.3. Endogenous peroxidase was inactivated by incubation with 3% hydrogen peroxide in methanol for 10 min at room temperature. ERα and PgR were detected using rabbit monoclonal anti-human ERα (1:200 dilution) and anti-human PgR (1:100 dilution) as primary antibodies, respectively.
peroxidase-conjugated goat anti-rabbit antibody for mouse tissue was used as secondary antibody, and a 3, 3'-diaminobenzidine tetrahydrochloride solution containing 0.003% hydrogen peroxide was added as the substrate followed by Mayer's hematoxylin solution added as counterstain.

Negative control samples were processed without applying the primary antibodies. Three fields of each sample were randomly selected for qualitative analysis without using an unblinded procedure; three slides were evaluated for each treatment group. Approximately, 300 cells/field were counted at a magnification of 400×, except in the necrotic area of the central tumor and the connective tissues or blood vessels.

Statistical analysis. The significance of the differences in the mean tumor volume between the treated and control groups on day 14 was analyzed using the Dunnett’s test. The combinational effect of S-1 and fulvestrant was analyzed according to the closed testing procedure using the Aspin–Welch two-tailed t-test (29). The significance of the differences in the mean uterine weight on day 1 was analyzed using the Aspin–Welch two-tailed t-test. The statistical analyses were performed using EXSAS, Ver. 7.11 (Arm Systex Co., Ltd., Osaka, Japan).

Results

In-vitro growth inhibition. The single-drug treatment with chemotherapeutic agent 5-FU inhibited the growth of both ER-positive MCF-7 and ER-negative MDA-MB-231 cells in a dose-dependent manner (Figure 1A). Fulvestrant alone inhibited the growth of MCF-7 cells but not of MDA-MB-231 cells (Figure 1B). The IC50 values of 5-FU for MCF-7 and MDA-MB-231 were 4.6 and 12.0 μM, respectively, and their ratio was 2.6, whereas the respective IC40 values of fulvestrant were 0.8 nM and >1 μM and their ratio was >12,500.

In this study, the efficacy of the combination therapy using 5-FU and fulvestrant was assessed in MCF-7 cells. Interestingly, the isobologram data points for the combination therapy of MCF-7 cells were located either within the envelope of additivity or below the envelope, indicating supra-additive effects (Figure 2). Hence, the combination of 5-FU and fulvestrant appears to have a beneficial effect.
In vivo antitumor activity. As shown in Figure 3, tumor volume reached a plateau on day 15; therefore, S-1 administration was terminated on day 18, and antitumor effects were evaluated based on the tumor volume on day 14. Importantly, tumor growth was significantly inhibited by S-1 or fulvestrant \((p<0.001)\). The tumor volume in the combination therapy group was significantly \((p<0.05)\) lower as compared to that in both monotherapy groups. Body weight loss was not observed during the experiment (data not shown).

Table I shows the uterine weight in mice without and with implanted SE-121 pellet containing 0.025 mg estradiol for 60 days release) had been subcutaneously implanted. Fulvestrant (5 mg/mouse) was administered subcutaneously on day one, S-1 (10 mg/kg) was administered orally once daily from day 1 to 18. Tumor volume was measured twice a week until day 19. The values are the means and SD of tumor volume \((n=7)\). Significantly different on day 15 at \(**p<0.001\) vs. control by Dunnett’s test; \(^a\)\(p<0.05\) vs. either monotherapy by Aspin–Welch t-test.

**Discussion**

In vitro combination treatment of estrogen-responsive MCF-7 breast cancer cells with 5-FU and fulvestrant was associated with additive or supra-additive effects. Combination therapy reduced tumor growth more significantly than either monotherapy, which had a more limited reduction in tumor volume relative to the starting volume. Tumoral ER\(\alpha\) expression, which was targeted by fulvestrant, was partially reduced by the treatment with this drug, whereas the combination therapy more significantly reduced the expression of ER\(\alpha\) than did each monotherapy. These results appeared to corroborate the synergistic cytotoxic effects of 5-FU and fulvestrant observed in vitro.

In our previous report, 4-hydroxytamoxifen and estrogen-depleted FBS, which mimics the effect of aromatase inhibitor activity in vitro, were shown to increase the activity of fluoropyrimidine (12, 13). In addition, combination therapy using the aromatase inhibitor anastrozole combined with S-1 or UFT was reported to be superior to both monotherapies (22). Furthermore, fulvestrant has been reported to reduce signaling via ER\(\alpha\) by down-regulating the ER\(\alpha\) level. The effects of the S-1/fulvestrant combination on MCF-7, a tumorigenic cell line with ER\(\alpha\) expression, were similar to those of other chemo-endocrine therapies using an anti-estrogen (4-hydroxytamoxifen) and an aromatase inhibitor (anastrozole) (12, 13, 22).

An in vivo analysis of the combination of fulvestrant and 5-FU in MCF-7-bearing nude mice has been already reported by Ogasawara et al. (30); the antitumor activity, 5-FU level, and the effect on tumor-associated mRNA was significantly increased, whereas the tumoral ER\(\alpha\) level was reduced as compared to that in the 5-FU monotherapy group (30). Interestingly, these results are corroborated by the data from our study. In a previous study, S-1 treatment significantly reduced tumoral mRNA expression of ER (22). Because fulvestrant down-regulates ER\(\alpha\) protein in tumor by

---

**Table I. Weight of uterus in nude mice (mean±SD).**

| Treatment                                | Uterine weight (g) | n  | \(p\)-Value* |
|------------------------------------------|--------------------|----|--------------|
| SE-121 and tumor-free                    | 0.066±0.009        | 8  |              |
| SE-121 alone                             | 0.097±0.031        | 7  | <0.05\(^a\)  |
| Fulvestrant and SE-121                   | 0.035±0.010        | 6  | <0.01\(^b\)  |

*Aspin-Welch two-tailed t-test. \(^a\)Versus SE-121 free; \(^b\)versus SE-121 alone.

---

In vivo antitumor activity. As shown in Figure 3, tumor volume reached a plateau on day 15; therefore, S-1 administration was terminated on day 18, and antitumor effects were evaluated based on the tumor volume on day 14. Importantly, tumor growth was significantly inhibited by S-1 or fulvestrant \((p<0.001)\). The tumor volume in the combination therapy group was significantly \((p<0.05)\) lower as compared to that in both monotherapy groups. Body weight loss was not observed during the experiment (data not shown).

Table I shows the uterine weight in mice without and with implanted SE-121 pellet containing 0.025 mg E\(_2\) that were either treated or not treated with fulvestrant. The SE-121 pellet significantly \((p<0.05)\) increased the uterine weight, and this increase was completely inhibited by concomitant fulvestrant treatment \((p<0.01)\) according to the Aspin–Welch t-test.

**IHC analysis of ER-\(\alpha\) and PgR.** ER\(\alpha\) and PgR were detected in the MCF-7 xenografts by IHC staining. The intensity and proportion of staining for ER\(\alpha\) was partially reduced by fulvestrant, whereas S-1 alone did not appear to affect ER\(\alpha\) staining. However, the combination therapy significantly reduced the intensity and proportion of cells staining for ER\(\alpha\) as compared to that of both monotherapies. PgR expression was barely detectable in the group treated with fulvestrant alone, although ER\(\alpha\) expression was only partially reduced, indicating that the ER\(\alpha\) transduction signal was reduced (Figure 4).
accelerated degradation and not by suppression of translation/transcription, the addition of S-1 contributed to the down-regulation of ERα.

In comparison with other standard chemotherapeutic agents, S-1 has some advantages. Specifically, for long-term treatment, this oral drug appears to be more beneficial than intravenous therapy. Furthermore, an open-label randomized phase III trial (SELECT BC) demonstrated that S-1 was non-inferior to taxane, a key drug for breast cancer with respect to overall survival, which is used as first-line therapy in metastatic breast cancer and associated with improved quality of life (21). It has been reported that patients with incurable cancer clearly prefer oral chemotherapy as compared to other administration routes if the efficacy is equivalent without reducing the quality of life, which also contributes to better medication adherence (31). The toxicities of S-1 and fulvestrant do not overlap in patients (19, 20, 23-25). Hair loss is a common adverse effect that severely reduces quality of life, especially for female patients, but the frequency of hair-loss associated with S-1 is low (less than 5%) in contrast with other standard chemotherapies, such as taxanes or anthracyclines (20, 32).

This study used only MCF-7 cells due to the limited availability of established tumorigenic human breast cancer cell lines which are responsive to estrogen. We also attempted to use T-47D, which is another typical ER-positive human breast cancer cell line, but failed to obtain in vivo growth of T-47D cells in a female nude or SCID mouse model (data not shown). In our current experiment, the maximum E2 dose of 0.025 mg, which did not induce renal toxicity, was used. Since this E2 dose significantly increased the uterine weight \((p<0.05)\), it appeared to be adequate for inducing the desired biological activity. However, the mechanism for potentiating ER degradation needs to be investigated further. Future studies should use patient-derived xenograft models that are ER-positive to assess the effects of fulvestrant and S-1.

In conclusion, chemo-endocrine therapy using S-1 in combination with fulvestrant may represent a new beneficial candidate therapy for menopausal patients with estrogen-responsive breast cancer that should be evaluated in clinical trials.

**Conflicts of Interest**

MN, HS, and TT are employees of Taiho Pharmaceutical Co., Ltd. SN has been an adviser for and received the honoraria and the research funding related to this study from Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan); SN has also been an adviser for and received the honoraria and the research funding not related to this study from AstraZeneca (Cambridge, UK). This study was funded by Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan). The Authors have no conflict of interest to declare regarding this study.

**Authors’ Contributions**

MN and TT planned the experiments. MN is the corresponding Author and wrote the article. HS and MN carried out the experiments. SN contributed to the interpretation of the results. All Authors provided critical feedback and helped shape the research, analysis, and article.

**Acknowledgements**

The Authors would like to thank Editage (www.editage.jp) for English language editing.
References

1 Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin 68: 7-30, 2018. PMID: 29313949. DOI: 10.3322/ caac.21442

2 Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Kordseja L, Khatceressian JL, Mehta RS, Muss HB and Burstein HJ: Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol 34: 3069-3103, 2016. PMID: 27271461. DOI: 10.1200/JCO.2016.67.1487

3 Vital Statistics Japan (Ministry of Health, Labour and Welfare). Available at: https://ganjoho.jp/reg_stat/statistics/dl/index.html

4 Sonoo H, Kurebayashi J, Iino Y, Inai H, Watanabe T, Toi M, Kobayashi S, Sato B and Yoshimoto M: Current status and controversial issues concerning endocrine therapy for patients with recurrent breast cancer in Japan. Breast Cancer 6: 344-355, 1999. PMID: 11091741.

5 Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA, Masuda N, Loi S, André F, Harbeck N, Verma S, Folkard E, Puyana Theall K, Hoffman J, Zhang K, Bartlett CH and Dowsett M: Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. Oncologist 22: 1026-1038, 2017. PMID: 28652278. DOI: 10.1634/theoncologist.2017-0072

6 Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T and Jerusalem G: Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36: 2465-2472, 2018. PMID: 29860922. DOI: 10.1200/JCO.2018.78.9909

7 Sledge GW Jr., Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdauer O, Okera M, Masuda N, Kaufman PA, Koj H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N and Llombart-Cussac A: MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2– advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 35: 2875-2884, 2017. PMID: 28580882. DOI: 10.1200/JCO.2017.73.7585

8 Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B, Forero-Torres A, Lee SC, de Boer R, Petrakova K, Valentinis S, Perez EA, Piccart M, Ellis M, Yannelli E, Dharan B, Sellami D and Bachelot T: Buparlisib plus fulvestrant in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19: 87-90, 2018. PMID: 29223745. DOI: 10.1016/S1470-2045(17)30688-5

9 Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiello-Gruszfeld A, Pestilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Bharan D, Di Tomaso E, Urban P, Massacesi C and Campone M: Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18: 904-916, 2017. PMID: 28576675. DOI: 10.1016/S1470-2045(17)30376-5

10 Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, O’Regan R, Mouret-Reynier MA, Kaele D, Egle D, Csósz T, Bordonaro R, Decker T, Tjan-Heijnen VCG, Blau S, Schirone A, Weber D, El-Hashimy M, Dharan B, Sellami D and Bachelot T: Buparlisib plus fulvestrant in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19: 87-90, 2018. PMID: 29223745. DOI: 10.1016/S1470-2045(17)30688-5

11 Cardoso F, Harbeck N, Fallowfield L, Kyriakides S and Senkus E: ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7): vii11-9, 2012. DOI: 10.1093/annonc/mds269

12 Noguchi S, Koyama H, Uchino J, Abe R, Miura S, Sugimachi K, Akazawa K and Abe O: Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: A pooled analysis of six randomized controlled trials. J Clin Oncol 23: 2172-2184, 2005. PMID: 15800310. DOI: 10.1200/JCO.2005.02.158

13 Ohashi Y, Watanabe T, Sano M, Koyama H, Inai H and Suzuki T: Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: A pooled analysis of two randomized controlled trials (NSAS-BC 01 trial and CUBC trial) Breast Cancer Res Treat 119: 633-641, 2010. PMID: 19936917. DOI: 10.1007/s10549-009-0635-3

14 Park Y, Okamura K, Mitsuyama S, Saito T, Koh J, Kyono S, Higaki O, Ogita M, Asaga T, Inai H, Komichi H, Kohno N, Yamazaki K, Tanaka F, Ito T, Nishikawa H, Osaki A, Koyama H and Suzuki T: Uracil-tegafur and tamoxifen vs. cyclophosphamide, methotrexate, 5-fluorouracil and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: A comparative study. Br J Cancer 101: 598-604, 2009. PMID: 19638976. DOI: 10.1038/sj.bjc.6605218

15 Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K, Sonoo H, Tsuda H, Sakamoto G and Ohashi Y: Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. J Clin Oncol 27: 1368-1374, 2009. PMID: 19204202. DOI: 10.1200/JCO.2008.18.3939

16 Kurebayashi J, Nakatsuka M, Nagase H, Nomura T, Hirono M, Yamamoto Y, Sugimoto Y, Oka T and Sonoo H: Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells. Cancer Chemother Pharmacol 59: 515-525, 2007. PMID: 16900372. DOI: 10.1007/s00280-006-0293-7

17 Kurebayashi J, Nakatsuka M, Sonoo H, Uchida J and Kiniwa M: Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer. Cancer Chemother Pharmacol 65: 219-225, 2010. PMID: 19455332. DOI: 10.1007/s00280-009-1024-7
18 Shirasaka T, Nakano K, Takechi T, Saito H, Okabe H, Oyama K, Takeda S, Unemi N and Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotypically implanted into nude rats. Cancer Res 56: 2602-2606, 1996. PMID: 8653704.

19 Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T, Okabe H, Fujioka A, Nakano K, Ohshima H, Takeda S and Shirasaka T: Preclinical antitumor efficacy of S-1: A new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 13: 693-698, 1998. PMID: 9735397. DOI: 10.3892/ijo.13.4.693

20 Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Hibagisho M, Yamamura Y, Kurita A and Arai K; ACTS-GC Group: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357: 1810-1820, 2007. PMID: 17978289. DOI: 10.1056/NEJMoa072252

21 Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y and SELECT BC Study Group: Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): An open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 17: 90-98, 2016. PMID: 26617202. DOI: 10.1016/S1470-2045(15)00411-8

22 Nukatsuka M, Saito H, Nakagawa F, Abe M, Uchida J, Shibata J, Matsu K, Noguchi S and Kiniwa M: Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts. Breast Cancer Res Treat 128: 381-390, 2011. PMID: 20809360. DOI: 10.1007/s10549-010-1141-3

23 Dauvois S, Danielian PS, White R and Parker MG: Antiestrogen ICI 164, 384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89: 4037-4041, 1992. PMID: 1570330. DOI: 10.1073/pnas.89.9.4037

24 Wakeling AE, Dukes M and Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867-3873, 1991. PMID: 1855205.

25 Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gerltler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R and Buzdar A: Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 20: 3386-3395, 2002. PMID: 12177098. DOI: 10.1200/JCO.2002.10.058

26 Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I and Osborne CK: Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 22: 1605-1613, 2004. PMID: 15117982. DOI: 10.1200/JCO.2004.02.112

27 Saotome K, Morita H and Umeda M: Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs. Toxicol In Vitro 3: 317-321, 1989. PMID: 20702298.

28 Fivevelm QL, Adagu IS and Warhurst DC: Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob Agents Chemother 48: 4097-4102, 2004. PMID: 15504827. DOI: 10.1128/AAC.48.11.4097-4102.2004

29 Bauer P, Röhmel J, Maurer W and Hothorn L: Testing strategies in multi-dose experiments including active control. Stat Med 17: 2133-2146, 1998. PMID: 9789919.

30 Ogasawara Y, Doihara H, Shiroma K, Kanaya Y and Shimizu N: Effects of experimental chemooendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice. Surg Today 29: 149-156, 1999. PMID: 10030740. DOI: 10.1007/BF02482240

31 Liu G, Franssen E, Fitch MI and Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110-115, 1997. PMID: 8996131. DOI: 10.1200/JCO.1997.15.1.110

32 Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Sow RA, Yang JC, Sugawara S, Nishio M, Takahashi T, Goto K, Chang J, Maemondo M, Ichinose Y, Cheng Y, Lim WT, Morita S and Tamura T: Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Ann Oncol 28: 2698-2706, 2017. PMID: 29045553. DOI: 10.1093/annonc/mdx419

Received May 20, 2019
Revised June 21, 2019
Accepted July 4, 2019